Targeted siRNA delivery by anti-HER2 antibody-modified nanoparticles of mPEG-chitosan diblock copolymer

Journal of Biomaterials Science, Polymer Edition

Volumn 24, Issue 10, 2013, Pages 1219-1232

  Wang, Yiyi ^a   Liu, Peifeng ^b   Du, Jing ^a   Sun, Ying ^b   Li, Fenghua ^a   Duan, Yourong ^b  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

mPEG CS siRNA targeting delivery nanoparticles

Indexed keywords

ENCAPSULATION EFFICIENCY; EPIDERMAL GROWTH FACTOR RECEPTORS; GLYCOL CHITOSAN; HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2); PHYSICOCHEMICAL PROPERTY; SMALL INTERFERING RNA (SIRNA); TARGETING DELIVERIES; ZETA POTENTIAL ANALYZERS;

ANTIBODIES; BLOCK COPOLYMERS; CHITOSAN; ENCAPSULATION; LIPOSOMES; NANOPARTICLES; RNA; ZETA POTENTIAL;

MOTION PICTURE EXPERTS GROUP STANDARDS;

EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; LIPOFECTAMINE; MONOMETHOXY POLYETHYLENE GLYCOL CHITOSAN NANOPARTICLE; NANOPARTICLE; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ARTICLE; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; GENE DELIVERY SYSTEM; HUMAN; HUMAN CELL; IN VITRO STUDY; NANOENCAPSULATION; PARTICLE SIZE; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; SPECTROPHOTOMETER; SURFACE CHARGE; ZETA POTENTIAL;

ANTIBODIES; CELL LINE; CHITOSAN; DRUG CARRIERS; HUMANS; NANOPARTICLES; POLYETHYLENE GLYCOLS; POLYMERS; RECEPTOR, ERBB-2; RNA, SMALL INTERFERING;

EID: 84878707314     PISSN: 09205063     EISSN: 15685624     Source Type: Journal    
DOI: 10.1080/09205063.2012.745716     Document Type: Article

References (44)

1. Fuchs U, Borkhardt A. The application of siRNA technology to cancer biology discovery. Adv. Cancer Res. 2007;96:75-102.
2. Oh YK, Park TG. siRNA delivery systems for cancer treatment. Adv. Drug Delivery Rev. 2009;61:850-862.
3. Veiseh O, Kievit FM, Gunn JW, Ratner BD, Zhang M. A ligand-mediated nanovector for targeted gene delivery and transfection in cancer cells. Biomaterials. 2009;30:649-657.
4. Higuchi Y, Kawakami S, Hashida M. Strategies for in vivo delivery of siRNAs: recent progress. Bio. Drugs. 2010;24:195-205.
5. Li SD, Chen YC, Hackett MJ, Huang L. Tumor-targeted delivery of siRNA by self-assembled nanoparticles. Mol. Ther. 2007;16:163-169.
6. Li SD, Chono S, Huang L. Efficient gene silencing in metastatic tumor by siRNA formulated in surface-modified nanoparticles. J. Control Release. 2008;126:77-84.
7. Peer D, Park EJ, Morishita Y, Carman CV, Shimaoka M. Systemic leukocyte-directed siRNA delivery revealing cyclin D1 as an anti-inflammatory target. Science. 2008;319:627-630.
8. Xu Z, Gu W, Chen L, Gao Y, Zhang Z, Li Y. A smart nanoassembly consisting of acid-labile vinyl ether PEG-DOPE and protamine for gene delivery: preparation and in vitro transfection. Biomacromolecules. 2008;9:3119-3126.
9. Park YJ, Liang JF, Ko KS. Low molecular weight protamine as an efficient and nontoxic gene carrier: in vitro study. J. Gene Med. 2003;5:700-711.
10. Song E, Zhu PC, Lee SK, Chowdhury D, Steven K, Derek MD, Yi F, Deborah P, David WB, Premlata S, Wayne MA, Judy L. Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors. Nat. Biotechnol. 2005;23:709-717.
11. Liu Z, Mark W, Mark H, Dai H. siRNA delivery into human T cells and primary cells with carbon-nanotube transporters. Angew. Chem. Int. Ed.Engl. 2007;46:2023-2027.
12. Medarova Z, Pham W, Farrar C, Petkova V, Moore A. In vivo imaging of siRNA delivery and silencing in tumors. Nat. Med. 2007;13:372-377.
13. Zhang SL, Li J, Lykotrafitis G, Bao G, Suresh S. Size-dependent endocytosis of nanoparticles. Adv. Mater. 2009;21:419-424.
14. Petros RA, Desimone JM. Strategies in the design of nanoparticles for therapeutic applications. Nat. Rev. Drug Discov. 2010;9:615-627.
15. Woodrow KA, Cu Y, Booth CJ, Saucier-Sawyer JK, Wood MJ, Saltzman WM. Intravaginal gene silencing using biodegradable polymer nanoparticles densely loaded with small-interfering RNA. Nat. Mater. 2009;8:526-533.
16. Liu PF, Qi XL, Sun Y, Wang HZ, Li YG, Duan YR. RGD-conjugated PLA-PLL nanoparticles targeting to Bacp-37 breast cancer xenografts in vivo. J. Nanosci. Nanotechnol. 2011;11:10760-10764.
17. Zhang JX, Sun HL, Ma PX. Host-guest interaction mediated polymeric assemblies: multifunctional nanoparticles for drug and gene delivery. ACS Nano. 2010;4:1049-1059.
18. Howard KA, Rahbek UL, Liu XD, Damgaard CK, Glud SZ, Andersen MØ, Hovgaard MB, Schmitz A, Nyengaard JR, Besenbacher F, Kjems J. RNA interference in vitro and in vivo using a novel chitosan/siRNA nanoparticle system. Mol. Ther. 2006;14:476-484.
19. Katas H, Alpar HO. Development and characterisation of chitosan nanoparticles for siRNA delivery. J. Control Release. 2006;115:216-225.
20. Pillé JY, Li H, Blot E, Bertrand JR, Pritchard LL, Opolon P. Intravenous delivery of anti-RhoA small interfering RNA loaded in nanoparticles of chitosan in mice: safety and efficacy in xenografted aggressive breast cancer. Hum. Gene Ther. 2006;17:1019-1026.
21. Aktas Y, Yemisci M, Andrieux K, Gursoy RN, Alonso MJ, Fernandez-Megia E. Development and brain delivery of chitosan-PEG nanoparticles functionalized with the monoclonal antibody OX26. Bioconjugate Chem. 2005;16:1503-1511.
22. Prego C, Torres D, Fernandez-Megia E, Novoa-Carballal R, Quinoa E, Alonso MJ. Chitosan-PEG nanocapsules as new carriers for oral peptide delivery. Effect of chitosan pegylation degree. J. Control Release. 2006;111:299-308.
23. Rafat M, Li F, Fagerholm P, Lagali NS, Watsky MA, Munger R. PEG-stabilized carbodiimide crosslinked collagen-chitosan hydrogels for corneal tissue engineering. Biomaterials. 2008;29:3960-3972.
24. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A, Press MF. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 1989;244:707-712.
25. Hung MC, Lau YK. Basic science of HER-2/neu: a review. Semin. Oncol. 1999;26:51-59.
26. Ignatoski KM, Maehama T, Markwart SM, Dixon JE, Livant DL, Ethier SP. ERBB-2 overexpression confers PI 3' kinase-dependent invasion capacity on human mammary epithelial cells. Br. J. Cancer. 2000;82:666-674.
27. Jiang S, Zhang Y, Lim KM, Sim EKW, Ye L. NIR-to-visible upconversion nanoparticles for fluorescent labeling and targeted delivery of siRNA. Nanotechnology. 2009;20:155101-155109.
28. Gao J, Sun J, Li HM, Liu W, Zhang Y, Li BH, Qian WZ, Wang H, Chen JM, Guo YJ. Lyophilized HER2-specific PEGylated immunoliposomes for active siRNA gene silencing. Biomaterials. 2010;31:2655-2664.
29. Yao YD, Sun TM, Huang SY, Dou S, Lin L, Chen JN, Ruan JB, Mao CQ, Yu FY, Zeng MS, Zang JY, Liu Q, Su FX, Peter Z, Judy L, Wang J, Song E. Targeted delivery of PLK1-siRNA by ScFv suppresses Her2+ breast cancer growth and metastasis. Sci. Transl. Med. 2012;4:130ra48.
30. Kalchar HM. Differential spectrophotometry of purine compounds by means of specific enzymes: studies of the enzymes of purine metabolism. J. Biol. Chem. 1947;167:461-475.
31. Pittella F, Zhang M, Lee Y, Kim HJ, Tockary T, Osada K, Ishii T, Miyata K, Nishiyama N, Kataoka K. Enhanced endosomal escape of siRNA-incorporating hybrid nanoparticles from calcium phosphate and PEG-block charge-conversional polymer for efficient gene knockdown with negligible cytotoxicity. Biomaterials. 2011;32:3106-3114.
32. Cun D, Jensen DK, Maltesen MJ, Bunker M, Whiteside P, Scurr D, Foged C, Nielsen HM. High loading efficiency and sustained release of siRNA encapsulated in PLGA nanoparticles: quality by design optimization and characterization. Eur. J. Pharm. Biopharm. 2011;77:26-35.
33. Xing YL, Xiang YK, Shuai S, Xiu HW, Ying CG, Gang G, Yong QM, Feng L, Xia Z, Yu QW, Zhi YQ. Preparation, characterization, and self-assembly behavior of a novel MPEG/PCL-g-Chitosan copolymer. Soft Mater. 2010;8:320-337.
34. Hu YQ, Jiang HL, Xu CN, Wang YJ, Zhu KJ. Preparation and characterization of poly(ethylene glycol)-g-chitosan with water-and organosolubility. Carbohydr. Polym. 2005;61:472-479.
35. Gaspar VM, Sousa F, Queiroz JA, Correia IJ. Formulation of chitosan-TPP-pDNA nanocapsules for gene therapy applications. Nanotechnology. 2011;22:015101.
36. De Moura MR, Aouada FA, Avena-Bustillos RJ, McHugh TH, Krochta JM, Mattoso LHC. Properties of novel hydroxypropyl methylcellulose films containing chitosan nanoparticles. J. Food Eng. 2009;92:448-453.
37. Mo Y, Lim LY. Paclitaxel-loaded PLGA nanoparticles: potentiation of anticancer activity by surface conjugation with wheat germ agglutinin. J. Control Release. 2005;108:244-262.
38. Wang H, Song S, Kou G, Li B, Zhang D, Hou S, Qian W, Dai J, Tian L, Zhao J, Guo Y. Treatment of hepatocellular carcinoma in a mouse xenograft model with an immunotoxin which is engineered to eliminate vascular leak syndrome. Cancer Immunol. Immun. 2007;56:1775-1783.
39. Zhang HL, Wu SH, Tao Y, Zang LQ, Su ZQ. Preparation and characterization of water-Soluble chitosan nanoparticles as protein delivery system. J. Nanomater. 2010;20:1-5.
40. Chen HW, Gao J, Lu Y, Kou G, Zhang H, Fan L, Sun ZG, Guo YJ, Zhong YQ. Preparation and characterization of PE38KDEL-loaded anti-HER2 nanoparticles for targeted cancer therapy. J. Control Release. 2008;128:209-216.
41. Qi XL, Chen XY, Sun Y, Ma ZC, Guo XJ, Lu W, Duan YR. Cytotoxicity and cellular uptake evaluation of mitoxantrone-loaded poly (lactic acid-co-lysine) arginine-glycine-aspartic acid nanoparticles. J. Appl. Polym. Sci. 2011;119:1011-1015.
42. Magenheim B, Levy MY, Benita S. A new in vitro technique for evaluation of drug release profile from colloidal carriers-ultrafiltration technique at low pressure. Int. J. Pharm. 1993;94:115-123.
43. Acharya G, Shin CS, Vedantham K, McDermott M, Rish T, Hansen K, Fu Y, Park K, Hansen K. A study of drug release from homogeneous PLGA microstructures. J. Control Release. 2010;146:201-206.
44. Quaglia F, Ostacolo L, Mazzaglia A, Villari V, Zaccaria D, Sciortino MT. The intracellular effects of non-ionic amphiphilic cyclodextrin nanoparticles in the delivery of anticancer drugs. Biomaterials. 2009;30:374-382.